SCHEDULE: Vanguard Group Reports 0% Stake in Amicus Therapeutics

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Amicus Therapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 9 to Schedule 13G regarding its beneficial ownership of Amicus Therapeutics Inc. Common Stock.
• As of March 13, 2026, The Vanguard Group reports 0% aggregate beneficial ownership in Amicus Therapeutics Inc.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report their beneficial ownership separately.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such disaggregated subsidiaries and/or business divisions, in accordance with SEC Release No. 34-39538.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative development for Amicus Therapeutics, as a major institutional investor's parent entity now reports 0% beneficial ownership, despite the explanation of internal realignment.

Positives

• The reported change in ownership is due to an internal organizational realignment by The Vanguard Group, not necessarily a complete divestment of the underlying shares from Vanguard's broader managed funds.

Negatives

• The Vanguard Group, as the primary reporting entity, no longer reports any beneficial ownership in Amicus Therapeutics Inc., which could be perceived negatively by some investors.

Management Comments

• The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.
• I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that while this filing indicates The Vanguard Group, Inc. itself no longer reports beneficial ownership, it is due to an internal restructuring rather than a complete divestment of Amicus Therapeutics shares by all Vanguard-managed funds. This type of internal realignment for reporting purposes is not uncommon among large asset managers and does not necessarily reflect a change in investment thesis for the underlying company by Vanguard's various investment products.

Stakeholder Impact

• Shareholders: May perceive a reduction in institutional ownership, potentially leading to negative sentiment or increased scrutiny, even if the underlying shares are still held by Vanguard's subsidiaries.

Key Dates

Recommendation

The filing indicates a significant change in reported beneficial ownership by The Vanguard Group, moving to 0%. While explained by an internal realignment, this could create uncertainty or negative sentiment among investors. However, it does not necessarily mean a complete divestment of Amicus Therapeutics shares by all Vanguard-managed funds. Investors should hold and monitor for further clarity on the actual holdings by Vanguard's disaggregated entities and any impact on market sentiment.

Keywords

Amicus Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, SEC Filing, Common Stock, Ownership Change, Internal Realignment